Nav: Home

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable

February 06, 2020

Following the first U.S. test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies - for months. The results from this Phase 1 clinical trial suggest the gene editing approach was safe and feasible, which until now has been uncertain, and the findings represent an important step toward the ultimate goal of using gene editing to help a patient's immune system attack cancer. CRISPR-Cas9 gene editing provides a powerful tool to improve the natural ability of human T cells to fight cancer. Though engineered T cell therapies are greatly advancing cancer treatment, whether CRISPR-Cas9 edited T cells would be tolerated and survive once reinfused into a human has been unknown. Here, focusing on three patients in their 60s with advanced cancers that didn't respond to standard treatments, Edward A. Stadtmauer and colleagues sought to test this. They removed T lymphocytes from these patients' blood and used CRISPR to delete genes from the cells that might interfere with the immune systems's ability to fight cancer. Next, the researchers used a virus to arm the T-cells to attack a protein typically found on cancer cells, NY-ESO-1. They infused the cells back into the patients and monitored cell engraftment and persistence. There were no toxicity-related side effects, the authors report, and the engineered T cells could be detected up to 9-months post-infusion. The work builds on earlier research developing adoptive T cell therapies led by Dr. Carl June, who was also part of this study. In a related Perspective, Jennifer Hamilton and Jennifer Doudna write, "these findings provide the cell engineering field with a guide for the safe production and non-immunogenic administration of gene edited somatic cells." They add: "The big question that remains unanswered by this study is whether gene-edited, engineered T cells are effective against advanced cancer," while also noting that the study by Stadtmauer and colleagues was restricted to editing protocols available in 2016, in which gene-edited T cells are likely less effective than they would be using newer technology available today.
-end-


American Association for the Advancement of Science

Related Advanced Cancer Articles:

Advanced prostate cancer has an unexpected weakness that can be targeted by drugs
Kanazawa University researchers reported that the SUCLA2 gene is frequently involved in the deletion of the tumor suppressor gene RB1 in advanced prostate cancer.
Higher risk of death in cancer patients with COVID-19 may be due to advanced age and more pre-existing conditions, rather than cancer itself
New research presented at this this week's ESCMID Conference on Coronavirus Diseases (ECCVID, online 23-25 September) suggests that the poor outcomes and higher death rates in cancer patients with COVID-19 could be due to them generally being older and having more underlying conditions, rather than due to the cancer itself.
Olanzapine may help control nausea, vomiting in patients with advanced cancer
Olanzapine, a generic drug used to treat nervous, emotional and mental conditions, also may help patients with advanced cancer successfully manage nausea and vomiting unrelated to chemotherapy.
Being overweight may raise your risk for advanced prostate cancer
A new study links being overweight in middle age and later adulthood to a greater risk of advanced prostate cancer.
New advances in the treatment of advanced lung cancer
The University of Barcelona (UB) and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic and antifibrotic drug, for the treatment of lung cancer.
Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.
Advanced cancer drug shrinks and intercalates DNA
A new study published in EPJ E has found that the drug first forces itself between the strands of the DNA molecule's double helix, prising them apart.
Exercise associated with benefit to patients with advanced colorectal cancer
Patients with metastatic colorectal cancer who engaged in moderate exercise while undergoing chemotherapy tended to have delayed progression of their disease and fewer severe side effects from treatment, according to the results of a new study.
A new method to select the right treatment for advanced prostate cancer
Researchers at Karolinska Institutet in Sweden have identified blood-based biomarkers that may determine which patients will benefit from continued hormonal therapy for advanced prostate cancer.
New treatment approach for advanced anal cancer
A new approach to treating advanced anal cancer is safer and more effective than the most widely used current treatment, according to the first ever randomized clinical trial in this group of patients.
More Advanced Cancer News and Advanced Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.